Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation

Graham Scotland,1 Moira Cruickshank,2 Elisabet Jacobsen,1 David Cooper,2 Cynthia Fraser,2 Michal Shimonovich,2 Angharad Marks3 and Miriam Brazzelli2*

1Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
2Health Services Research Unit, University of Aberdeen, Aberdeen, UK
3NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK

*Corresponding author m.brazzelli@abdn.ac.uk

Declared competing interests of authors: none

Published January 2018
DOI: 10.3310/hta22010

Scientific summary

Multiple-frequency bioimpedance devices in chronic kidney disease
Health Technology Assessment 2018; Vol. 22: No. 1
DOI: 10.3310/hta22010

NIHR Journals Library www.journalslibrary.nihr.ac.uk
科学概述

背景

慢性肾病（CKD）是一种长期性状况，其中肾脏功能不正常。在CKD最严重的阶段，肾脏仅能正常工作至≤15%的功能，并且需要通过保守治疗、肾脏移植或透析来治疗。透析涉及清除血液中的废物和多余水分，有两种主要类型：

1. 血液透析（HD），其中患者连接到一个透析机，该机使用半透膜过滤血液中的多余盐分和水分；HD通常每周三次，每次四小时，在医院、卫星单位或家中进行。
2. 腹膜透析（PD），其中透析液被引入腹膜腔并通过永久性导管，废物和多余水分被血液中的血管从血液中抽出到透析液中。该过程的液体交换可以由机器（自动PD）在夜间进行，也可以由患者手动进行，每天四次，每次30-40分钟。

为了优化透析期间的液体量（以避免脱水或过量，这两者都可能与严重并发症相关），人们被分配一个‘目标体重’，通常通过临床方法来评估，如透析前后的体重变化，血压和患者报告的症状。然而，这些方法并不精确，无创、简单和便宜的生物电抗技术测量仪在透析中心越来越被使用。目前尚无关于生物电抗技术在CKD患者透析治疗中管理液体的临床有效性和成本效益的证据。

目标

该评估的具体目标是：

- 系统性地回顾多频率生物电抗设备（例如：Body Composition Monitor (BCM; Fresenius Medical Care, Bad Homburg vor der Höhe, Germany), MultiScan 5000 (Bodystat, Douglas, Isle of Man), BioScan 920-II (Maltron International, Essex, UK), BioScan touch i8 (Maltron International, Essex, UK) 和 InBody S10 (InBody, Seoul, South Korea)）与标准临床评估的比较
- 系统性地回顾多频率生物电抗设备的现有经济学评估
- 开发新的经济学评估模型来评估多频率生物电抗技术（使用BCM，MultiScan 5000，BioScan 920-II，BioScan touch i8或InBody S10）与标准临床评估相比在CKD患者透析治疗中管理液体的经济学和成本效益。
Methods

Clinical effectiveness

Comprehensive electronic searches were undertaken between June and October 2016 to identify relevant reports of published studies. There were no date restrictions. Databases searched included MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index and Cochrane Central Register of Controlled Trials (CENTRAL). Evidence was considered from randomised controlled trials (RCTs) assessing multiple-frequency bioimpedance devices versus standard clinical assessment, and non-randomised cohort studies. The population was people with CKD being treated with HD or PD. The comparator was standard clinical assessment, consisting of blood pressure, presence of oedema, changes in weight, residual renal function, pre-existing cardiovascular (CV) conditions and/or patient-reported symptoms of overhydration or underhydration.

Data on clinical outcomes, intermediate outcomes and patient-reported outcomes were extracted from the included studies. Binary and continuous data were meta-analysed (when appropriate) as pooled summary effect sizes using standard inverse variance methods.

Cost-effectiveness

A Markov model was developed to simulate the progression of the prevalent dialysis cohort through a set of mutually exclusive health states capturing mortality, CV events and other causes of hospitalisation, transplantation (for those listed) and graft failure post transplant. The model included costs to the health service of providing dialysis treatment, costs of inpatient hospitalisation, costs of outpatient attendance, costs of kidney transplantation, post-transplant follow-up and immunosuppressant costs and costs of dialysis following transplant graft failure. Health state utility multipliers were identified and incorporated for the dialysis and post-transplant states in the model, allowing cumulative quality-adjusted life-years (QALYs) to be estimated. Further proportional reductions in health state utility were modelled in the short term for all hospitalisation events and in the long term following incident CV hospitalisation events.

The added costs and plausible effects of bioimpedance-guided fluid management (based on four tests per year) were added to the baseline model, and the cumulative costs and QALYs were simulated over the lifetime of the cohort in the alternative arms of the model. In the base-case clinical effectiveness scenarios, proportional reductions in all-cause mortality and CV event-related or all-cause hospitalisation were applied in the bioimpedance-guided arm of the model. Given the limited direct evidence from the clinical effectiveness review, these effects [incorporated as hazard ratios (HRs)] were primarily estimated by linking effects on surrogate end points [arterial stiffness (pulse wave velocity; PWV) and hydration status] to possible effects on the final outcomes using secondary published sources.

Results

Clinical effectiveness

A total of five RCTs (published in six papers) analysing a total of 904 participants, and eight non-randomised studies (published in nine papers) analysing a total of 4915 participants were included in the review of clinical effectiveness. All included studies investigated the use of the BCM in the relevant population, all of which were adults. Of the RCTs, one trial was rated as having a high risk of bias, and four trials did not provide sufficient information to make a robust judgement. We further identified four ongoing trials.

The results of the meta-analyses conducted for this assessment showed that both absolute overhydration and relative overhydration were significantly lower in the BCM group than in the standard clinical assessment group [weighted mean difference −0.44, 95% confidence interval (CI) −0.72 to −0.15, p = 0.003, I² = 49%; and weighted mean difference −1.84, 95% CI −3.65 to −0.03, p = 0.05, I² = 52%, respectively]. The pooled effects of bioimpedance monitoring on blood pressure (mean difference −2.46, 95% CI −5.07 to 0.15; p = 0.06, I² = 0%), arterial stiffness (mean difference −1.18, 95% CI −3.14 to 0.78; p = 0.24, I² = 92%) and mortality (HR 0.689, 95% CI 0.23 to 2.08; p = 0.51, I² = 54%) were not statistically significant.
Evidence from non-randomised studies suggested that there were no statistically significant differences in blood pressure between the following subgroups: patients in whom overhydration was reduced within 6 months compared with those whose overhydration was not reduced within 6 months, patients receiving short-term versus long-term dialysis and patients who were normohydrated compared with those who were overhydrated.

**Cost-effectiveness**

Six main clinical effectiveness scenarios were explored in the cost-effectiveness modelling, with HRs of varying magnitude applied to all-cause mortality and CV event-related or all-cause hospitalisation rates. One of the scenarios also explored the impact of modelling a reduction in the use (cost) of blood pressure medication with bioimpedance-guided fluid management. There was insufficient evidence to justify the inclusion of effects on dialysis requirements (number and duration of sessions), residual renal function and the health-related quality of life of patients receiving dialysis (independent of effects on hospitalisation).

When dialysis costs were included in the model, the incremental cost-effectiveness ratios (ICERs) for bioimpedance-guided fluid management ranged from £58,723 to £66,007 per QALY gained. These ICERs related to mean incremental costs that varied between £4518 and £35,676, and corresponding lifetime incremental QALY gains that varied from 0.07 to 0.58. The costs of dialysis in added years made up the vast majority of the incremental costs. When dialysis costs were excluded from the model, the base-case ICERs ranged from £15,215 to £21,201.

**Sensitivity analyses**

Beyond the inclusion/exclusion of dialysis costs, the cost-effectiveness results were found to be most sensitive to the effect of bioimpedance-guided fluid management on all-cause mortality. When dialysis costs were included in the model, the ICER was most favourable (≈ £40,300) when the HR for all-cause mortality was set equal to one, that is, no reduction in mortality leading to no extra dialysis costs, but retained benefits on non-fatal hospitalisation events. With dialysis costs and an effect on mortality included in the model, there would need to be an accompanying effect of bioimpedance monitoring on the cost of dialysis and/or health state utility over the lifetime of patients receiving dialysis. There is currently limited available evidence to justify such scenarios.

When dialysis costs were excluded from the model, the ICER for bioimpedance-guided fluid management remained below £20,000 in most scenarios assessed. Given the relatively low cost of adding bioimpedance testing four times a year, the ICERs remained favourable with modest effects on mortality and hospitalisation rates. With dialysis costs excluded, probabilities of cost-effectiveness ranged from 61% to 67% at a willingness-to-pay threshold of £20,000 per QALY gained.

**Discussion**

**Strengths, limitations of the analyses and uncertainties**

The methods used to conduct this assessment were detailed and thorough. The main limitation was the lack of evidence on any of the specified devices, with the exception of the BCM, and on children receiving dialysis.

In light of the limited available clinical effectiveness evidence, the economic modelling relied on estimated effects on surrogate end points (hydration status, arterial stiffness and blood pressure) to model plausible reductions in all-cause mortality and CV event-related/all-cause hospitalisation. Critically, there were no ideal sources of evidence to link intervention-induced changes in the relevant surrogates to effects on mortality and hospitalisation rates. Therefore, the possible effects were informed by reference to cross-sectional prognostic studies, leading to great uncertainty in the robustness of the cost-effectiveness findings.
Generalisability of the findings
The included trials involved only the BCM, and it is not known if the effects of this device generalise across the other multiple-frequency bioimpedance devices specified for this appraisal. None of the included studies was conducted in the UK or involved paediatric populations, so the applicability of our findings in those contexts is unclear. The generalisability of the modelled cost-effectiveness scenarios is also dependent on the generalisability of the estimated pooled effects of bioimpedance-guided management on arterial stiffness (PWV) or inferred effects on hydration status. As all the included RCTs were conducted outside the UK, this remains uncertain.

Conclusions
Our findings indicate that both absolute overhydration and relative overhydration are significantly lower among people with CKD receiving dialysis who are managed using the BCM instead of standard clinical methods. The use of bioimpedance monitoring may reduce systolic blood pressure (SBP), although the pooled estimates of effects show a certain degree of heterogeneity and a non-significant effect. The current evidence does not demonstrate a significant effect on arterial stiffness and on mortality. There is currently no evidence to indicate that these findings are generalisable to paediatric populations or across other multifrequency bioimpedance devices. With possible effects on mortality and hospitalisation rates modelled indirectly through estimated pooled reductions in surrogate end points (PWV or overhydration), it appears unlikely that the ICER for bioimpedance-guided fluid management will fall below standard thresholds for cost-effectiveness with dialysis costs included. If dialysis costs are excluded from the model, the ICER may feasibly fall below £20,000, with modest effects on mortality and/or hospitalisation rates. The economic modelling is subject to substantial uncertainty, given the limitations in the clinical evidence base.

Implications for service provision
The current evidence suggests that BCM use, in addition to routine clinical assessment, may reduce overhydration and potentially improve intermediate outcomes such as SBP, but significant effects on mortality have not been demonstrated.

It would be useful if services that are currently, or subsequently, routinely using the BCM to augment routine clinical assessment could provide information on long-term outcomes before and after introduction of the bioimpedance device to extend the current evidence base.

Services that plan to introduce the routine use of the BCM to augment routine clinical assessment may consider adopting a protocol that is transparent and reproducible.

Suggested research priorities
The ultimate aim of introducing multiple-frequency bioimpedance device measurement in addition to standard clinical assessment into clinical practice is to reduce clinically important events such as mortality, CV events and hospital admissions, whether this is through a reduction in overhydration- or underhydration-related events. However, clinical effectiveness has not been demonstrated yet for these important health outcomes. The effects of introducing multiple-frequency bioimpedance device measurement on intermediate outcomes, such as SBP control and hydration status, have been documented. The timeline from these intermediate end points to those end points that are clinically relevant, however, may not be captured within the identified clinical trials. The studies were generally short-lived and the sustainability of introducing a change in routine practice has yet to be established.

Those centres that have introduced routine multiple-frequency bioimpedance device measurement to augment clinical assessment of dialysis patients may consider conducting adjusted retrospective analyses to estimate effects on clinically relevant and intermediate outcomes both before and after the introduction of the device. It would also be useful to obtain further information on the sustainability of the measurement and its use in clinical practice over a sustained period.
It is important that currently ongoing and future clinical trials are adequately powered to identify any clinical benefit (not just intermediate benefits) and the likely timeline of how any benefit (e.g. through better blood pressure control) is factored in to allow such studies to truly demonstrate whether or not an important clinical effect exists.

Future trials should adopt protocols that are likely to be clinically applicable in multiple areas (e.g. 3-monthly testing to allow use at routine review appointments).

Future trials should also carefully match their included population to the outcomes of interest. For example, if the primary outcome is a reduction in blood pressure, an appropriate clinical population would be patients who had high blood pressure and were fluid overloaded post HD, as they would be likely to have overhydration-related hypertension. Removing fluid from patients with hypertension who are not overhydrated may result in harm to some participants.

Related to further key uncertainties identified in the economic modelling, we recommend that future studies:

- assess the impact of hydration status and bioimpedance-guided fluid management on health-related quality of life, preferably using a generic preference-based instrument suitable for the estimation of QALYs
- assess the impact of bioimpedance testing on the frequency and duration of dialysis, and associated costs
- further develop and strengthen the evidence base for linking changes in surrogate end points (e.g. fluid management-induced changes in blood pressure and PWV) to changes in health outcomes (mortality, CV events, hospitalisation rates). Ideally, data from relevant randomised studies should be used to quantify relationships between intervention-induced changes in the surrogate end points and longer-term changes in health outcomes
- quantify the risks and cost burdens of different types of hospitalisation event in people receiving dialysis, and better characterise the impact of hydration status on these risks.

**Study registration**

This study is registered as PROSPERO CRD42016041785.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/17/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Scotland et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk